Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Danhuang Lvxin capsule
- Development stage
- Phase 2
- Lead developer
- Guizhou Yibai Pharmaceutical
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Danhuang Lvxin capsule is a traditional Chinese medicine (TCM) developed by Guizhou Baixiang Pharmaceutical Co., Ltd. for the treatment of chronic prostatitis. It is specifically indicated for patients presenting with the damp-heat downward flow pattern, a common TCM syndrome classification for prostatitis. The capsule is formulated to clear heat, resolve dampness, and alleviate symptoms associated with chronic inflammation of the prostate. It has been evaluated in randomized, double-blind, placebo-controlled Phase II clinical trials in China to assess its efficacy and safety in adult male patients.
Beyond the preview
Go deeper on Danhuang Lvxin capsule.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Danhuang Lvxin capsule.